Jade Biosciences, Inc. (JBIO) — Stock Price, Chart & Analysis
Jade Biosciences, Inc. (JBIO) is a Healthcare stock currently trading at $21.96, down 1.26% on the day. It carries a market capitalization of $1.34B. Over the past 52 weeks, JBIO has traded between $6.67 and $28.00. Jade Biosciences, Inc. does not currently pay a regular dividend. View the live JBIO chart, technical opinion, analyst ratings, fundamentals and latest news below.
Jade Biosciences, Inc. (JBIO) key data
| Price | $21.96 |
| Change (today) | -1.26% |
| Previous close | $22.24 |
| Market cap | $1.34B |
| EPS (TTM) | $-2.59 |
| 52-week high | $28.00 |
| 52-week low | $6.67 |
| Avg. volume | 1.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Jade Biosciences, Inc. (JBIO)
How much does one share of Jade Biosciences, Inc. cost?
As of the latest update, one share of Jade Biosciences, Inc. (JBIO) trades at $21.96 (-1.26% today).
What is Jade Biosciences, Inc.'s market cap?
Jade Biosciences, Inc. has a market capitalization of approximately $1.34B.
What is Jade Biosciences, Inc.'s earnings per share (EPS)?
Jade Biosciences, Inc.'s trailing twelve-month EPS is $-2.59.
Does Jade Biosciences, Inc. pay a dividend?
Jade Biosciences, Inc. does not currently pay a regular dividend.
What is Jade Biosciences, Inc.'s 52-week trading range?
Over the past year, JBIO has traded between $6.67 and $28.00.
What is the analyst price target for Jade Biosciences, Inc.?
The mean analyst price target for Jade Biosciences, Inc. is $48.50. This is informational only and not investment advice.
Latest Jade Biosciences, Inc. (JBIO) news
- Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?News · Jun 30, 2026
- Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsNews · Jun 26, 2026
- Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNews · Jun 5, 2026
- Jade Biosciences Announces Pricing of Public Offering of Common StockNews · Jun 4, 2026
- Jade Biosciences Announces Proposed Underwritten Public OfferingNews · Jun 3, 2026
- Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsNews · Jun 2, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live JBIO dashboard…